Beckman Coulter unveils DxC 500 AU chemistry analyser

Beckman Coulter Diagnostics is unveiling its new DxC 500 AU Chemistry Analyser, an automated clinical chemistry analyser, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyser is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories.

According to Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics, "Hub-and-spoke clinical laboratory models optimise resources to improve access to testing services and enhance overall standardisation for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyser advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes."

The product features advanced automation technology, onboard guided workflows, and standardised reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs.

The DxC 500 AU Chemistry Analyser is for in vitro diagnostic use only. It is available throughout North America and the Middle East. Global commercial availability is planned for March 2024.